{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:13:24Z","timestamp":1776276804536,"version":"3.50.1"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis Supplements"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/s1567-5688(15)30001-5","type":"journal-article","created":{"date-parts":[[2015,8,24]],"date-time":"2015-08-24T10:41:36Z","timestamp":1440412896000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"special_numbering":"C","title":["A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate\u2013statin combination therapy"],"prefix":"10.1016","volume":"19","author":[{"given":"Carlos","family":"Aguiar","sequence":"first","affiliation":[]},{"given":"Eduardo","family":"Alegria","sequence":"additional","affiliation":[]},{"given":"Riccardo C.","family":"Bonadonna","sequence":"additional","affiliation":[]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[]},{"given":"Francesco","family":"Cosentino","sequence":"additional","affiliation":[]},{"given":"Moses","family":"Elisaf","sequence":"additional","affiliation":[]},{"given":"Michel","family":"Farnier","sequence":"additional","affiliation":[]},{"given":"Jean","family":"Ferri\u00e8res","sequence":"additional","affiliation":[]},{"given":"Pasquale Perrone","family":"Filardi","sequence":"additional","affiliation":[]},{"given":"Nicolae","family":"Hancu","sequence":"additional","affiliation":[]},{"given":"Meral","family":"Kayikcioglu","sequence":"additional","affiliation":[]},{"given":"Alberto","family":"Mello e Silva","sequence":"additional","affiliation":[]},{"given":"Jesus","family":"Millan","sequence":"additional","affiliation":[]},{"given":"\u017deljko","family":"Reiner","sequence":"additional","affiliation":[]},{"given":"Lale","family":"Tokgozoglu","sequence":"additional","affiliation":[]},{"given":"Paul","family":"Valensi","sequence":"additional","affiliation":[]},{"given":"Margus","family":"Viigimaa","sequence":"additional","affiliation":[]},{"given":"Michal","family":"Vrablik","sequence":"additional","affiliation":[]},{"given":"Alberto","family":"Zambon","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Luis","family":"Zamorano","sequence":"additional","affiliation":[]},{"given":"Roberto","family":"Ferrari","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/S1567-5688(15)30001-5_bb0005","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1161\/01.CIR.82.2.495","article-title":"Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk","volume":"82","author":"Austin","year":"1990","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/S1567-5688(15)30001-5_bb0010","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1001\/jama.1988.03410130125037","article-title":"Low-density lipoprotein subclass patterns and risk of myocardial infarction","volume":"260","author":"Austin","year":"1988","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/S1567-5688(15)30001-5_bb0015","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1161\/ATVBAHA.109.190405","article-title":"Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk","volume":"29","author":"Musunuru","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"10.1016\/S1567-5688(15)30001-5_bb0020","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/01.ATV.16.8.1040","article-title":"Compositional differences of LDL particles in normal subjects with LDL subclass phenotype A and LDL subclass phenotype B","volume":"16","author":"Capell","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/S1567-5688(15)30001-5_bb0025","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2174\/157016111796642661","article-title":"\u201cEuropean panel on low density lipoprotein (LDL) subclasses\u201d: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses","volume":"9","author":"Mikhailidis","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"issue":"11","key":"10.1016\/S1567-5688(15)30001-5_bb0030","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/S1567-5688(15)30001-5_bb0035","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/j.1464-5491.2011.03360.x","article-title":"Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study","volume":"28","author":"Leiter","year":"2011","journal-title":"Diabet Med"},{"issue":"9","key":"10.1016\/S1567-5688(15)30001-5_bb0040","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.rce.2014.06.001","article-title":"Atherogenic dyslipidemia: prevalence and management in lipid clinics","volume":"214","author":"Pedro-Botet","year":"2014","journal-title":"Rev Clin Esp"},{"issue":"1","key":"10.1016\/S1567-5688(15)30001-5_bb0045","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jacl.2013.12.005","article-title":"Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia - full report","volume":"8","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"9753","key":"10.1016\/S1567-5688(15)30001-5_bb0050","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/S1567-5688(15)30001-5_bb0055","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"issue":"9841","key":"10.1016\/S1567-5688(15)30001-5_bb0060","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/S1567-5688(15)30001-5_bb0065","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jacl.2013.08.001","article-title":"High-density lipoproteins: a consensus statement from the National Lipid Association","volume":"7","author":"Toth","year":"2013","journal-title":"J Clin Lipidol"},{"issue":"10","key":"10.1016\/S1567-5688(15)30001-5_bb0070","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.molmed.2011.05.013","article-title":"Biological activities of HDL subpopulations and their relevance to cardiovascular disease","volume":"17","author":"Camont","year":"2011","journal-title":"Trends Mol Med"},{"issue":"3","key":"10.1016\/S1567-5688(15)30001-5_bb0075","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/cvr\/cvu147","article-title":"HDL-mediated mechanisms of protection in cardiovascular disease","volume":"103","author":"Kontush","year":"2014","journal-title":"Cardiovasc Res"},{"issue":"8","key":"10.1016\/S1567-5688(15)30001-5_bb0080","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.2337\/dc13-2738","article-title":"HDL-C and HDL-C\/ApoA-I predict long-term progression of glycemia in established type 2 diabetes","volume":"37","author":"Waldman","year":"2014","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/S1567-5688(15)30001-5_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5493\/wjem.v4.i1.1","article-title":"High density lipoproteins and type 2 diabetes: emerging concepts in their relationship","volume":"4","author":"Kostapanos","year":"2014","journal-title":"World J Exp Med"},{"issue":"9493","key":"10.1016\/S1567-5688(15)30001-5_bb0090","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"9607","key":"10.1016\/S1567-5688(15)30001-5_bb0095","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/S1567-5688(15)30001-5_bb0100","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.atherosclerosis.2013.09.020","article-title":"Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey","volume":"231","author":"Reiner","year":"2013","journal-title":"Atherosclerosis"},{"issue":"15","key":"10.1016\/S1567-5688(15)30001-5_bb0105","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/0002-9149(91)90924-A","article-title":"Prevalence of risk factors in men with premature coronary artery disease","volume":"67","author":"Genest","year":"1991","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/S1567-5688(15)30001-5_bb0110","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.amjcard.2009.04.008","article-title":"Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease","volume":"104","author":"Faergeman","year":"2009","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/S1567-5688(15)30001-5_bb0115","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","article-title":"Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial","volume":"51","author":"Miller","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10.1016\/S1567-5688(15)30001-5_bb0120","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/S1567-5688(15)30001-5_bb0125","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.amjcard.2010.05.002","article-title":"Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control","volume":"106","author":"Carey","year":"2010","journal-title":"Am J Cardiol"},{"issue":"24","key":"10.1016\/S1567-5688(15)30001-5_bb0130","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1016\/j.jacc.2010.01.050","article-title":"Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol","volume":"55","author":"Bayturan","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/S1567-5688(15)30001-5_bb0135","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ahj.2014.08.007","article-title":"Long-term risk of cardiovascular events across a spectrum of adverse major plasma lipid combinations in the Framingham Heart Study","volume":"168","author":"Andersson","year":"2014","journal-title":"Am Heart J"},{"issue":"9943","key":"10.1016\/S1567-5688(15)30001-5_bb0140","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/S1567-5688(15)30001-5_bb0145","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/S1567-5688(15)30001-5_bb0150","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1001\/jama.2008.621","article-title":"Nonfasting triglycerides and risk of ischemic stroke in the general population","volume":"300","author":"Freiberg","year":"2008","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/S1567-5688(15)30001-5_bb0155","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.jacc.2015.03.544","article-title":"Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins","volume":"65","author":"Schwartz","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/S1567-5688(15)30001-5_bb0160","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000381304","article-title":"Are elevated serum triglycerides really a risk factor for coronary artery disease?","volume":"131","author":"Reiner","year":"2015","journal-title":"Cardiology"},{"issue":"18","key":"10.1016\/S1567-5688(15)30001-5_bb0165","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/S1567-5688(15)30001-5_bb0170","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1161\/STROKEAHA.113.004229","article-title":"Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients","volume":"45","author":"Sirimarco","year":"2014","journal-title":"Stroke"},{"issue":"13","key":"10.1016\/S1567-5688(15)30001-5_bb0175","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/S1567-5688(15)30001-5_bb0180","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/01.ATV.11.3.569","article-title":"Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans","volume":"11","author":"Shaikh","year":"1991","journal-title":"Arterioscler Thromb"},{"issue":"1","key":"10.1016\/S1567-5688(15)30001-5_bb0185","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/01.ATV.12.1.6","article-title":"Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants","volume":"12","author":"Nordestgaard","year":"1992","journal-title":"Arterioscler Thromb"},{"issue":"4","key":"10.1016\/S1567-5688(15)30001-5_bb0190","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1161\/01.ATV.15.4.534","article-title":"Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media","volume":"15","author":"Nordestgaard","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/S1567-5688(15)30001-5_bb0195","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/S1567-5688(15)30001-5_bb0200","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehs431","article-title":"Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction","volume":"34","author":"J\u00f8rgensen","year":"2013","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/S1567-5688(15)30001-5_bb0205","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2337\/dc11-2556","article-title":"Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial","volume":"36","author":"Reyes-Soffer","year":"2013","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/S1567-5688(15)30001-5_bb0210","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.amjcard.2014.01.426","article-title":"Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease","volume":"113","author":"Zambon","year":"2014","journal-title":"Am J Cardiol"},{"issue":"13","key":"10.1016\/S1567-5688(15)30001-5_bb0215","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/S1567-5688(15)30001-5_bb0220","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/S1567-5688(15)30001-5_bb0225","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2013.06.024","article-title":"Lipoprotein remnants and dense LDL are associated with features of unstable carotid plaque: a flag for non-HDL-C","volume":"230","author":"Zambon","year":"2013","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/S1567-5688(15)30001-5_bb0230","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1055\/s-0034-1375675","article-title":"Costs of Diabetes Mellitus (CoDiM) in Germany, direct per-capita costs of managing hyperglycaemia and diabetes complications in 2010 compared to 2001","volume":"122","author":"Koster","year":"2014","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"6","key":"10.1016\/S1567-5688(15)30001-5_bb0235","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00019053-200927060-00004","article-title":"Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis","volume":"27","author":"Pelletier","year":"2009","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/S1567-5688(15)30001-5_bb0240","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.2337\/diacare.26.6.1790","article-title":"The health care costs of diabetic peripheral neuropathy in the US","volume":"26","author":"Gordois","year":"2003","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/S1567-5688(15)30001-5_bb0245","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2337\/dc10-1303","article-title":"Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments","volume":"33","author":"Tesfaye","year":"2010","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/S1567-5688(15)30001-5_bb0250","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrendo.2009.213","article-title":"Residual microvascular risk in diabetes: unmet needs and future directions","volume":"6","author":"Fioretto","year":"2010","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/S1567-5688(15)30001-5_bb0255","series-title":"Diabetic Retinopathy Guidelines","article-title":"The Royal College of Ophthalmologists","year":"2015"},{"issue":"9859","key":"10.1016\/S1567-5688(15)30001-5_bb0260","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(12)61689-4","article-title":"Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Murray","year":"2012","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/S1567-5688(15)30001-5_bb0265","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.numecd.2013.05.002","article-title":"Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update","volume":"23","author":"Reiner","year":"2013","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"10 Suppl","key":"10.1016\/S1567-5688(15)30001-5_bb0270","doi-asserted-by":"crossref","first-page":"1K","DOI":"10.1016\/j.amjcard.2008.10.002","article-title":"The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia","volume":"102","author":"Fruchart","year":"2008","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/S1567-5688(15)30001-5_bb0275","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3132\/dvdr.2008.046","article-title":"The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient","volume":"5","author":"Fruchart","year":"2008","journal-title":"Diab Vasc Dis Res"},{"issue":"1","key":"10.1016\/S1567-5688(15)30001-5_bb0280","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.diabet.2010.10.001","article-title":"Lipids, lipid-lowering therapy and diabetes complications","volume":"37","author":"Valensi","year":"2011","journal-title":"Diabetes Metab"},{"issue":"1","key":"10.1016\/S1567-5688(15)30001-5_bb0285","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.metabol.2011.05.004","article-title":"Triglyceride-high-density lipoprotein cholesterol is associated with microvascular complications in type 2 diabetes mellitus","volume":"61","author":"Zoppini","year":"2012","journal-title":"Metabolism"},{"issue":"11","key":"10.1016\/S1567-5688(15)30001-5_bb0290","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2337\/dc12-0306","article-title":"Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study","volume":"35","author":"Morton","year":"2012","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/S1567-5688(15)30001-5_bb0295","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1161\/CIRCULATIONAHA.113.002529","article-title":"Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case\u2013control study in 13 countries","volume":"129","author":"Sacks","year":"2014","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/S1567-5688(15)30001-5_bb0300","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2337\/dc10-0878","article-title":"Triglycerides and amputation risk in patients with diabetes: ten-year follow-up in the DISTANCE study","volume":"34","author":"Callaghan","year":"2011","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/S1567-5688(15)30001-5_bb0305","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.2337\/db08-1771","article-title":"Elevated triglycerides correlate with progression of diabetic neuropathy","volume":"58","author":"Wiggin","year":"2009","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/S1567-5688(15)30001-5_bb0310","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N Engl J Med"},{"issue":"9A","key":"10.1016\/S1567-5688(15)30001-5_bb0315","doi-asserted-by":"crossref","first-page":"3Q","DOI":"10.1016\/S0002-9149(98)00769-3","article-title":"Low-density lipoproteins and risk for coronary artery disease","volume":"82","author":"Ballantyne","year":"1998","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/S1567-5688(15)30001-5_bb0320","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.atherosclerosis.2014.09.026","article-title":"Combination therapy in dyslipidemia: where are we now?","volume":"237","author":"Catapano","year":"2014","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/S1567-5688(15)30001-5_bb0325","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.jacc.2004.03.046","article-title":"Optimal low-density lipoprotein is 50 to 70 mg\/dl: lower is better and physiologically normal","volume":"43","author":"O\u2019Keefe","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"9976","key":"10.1016\/S1567-5688(15)30001-5_bb0330","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/S1567-5688(15)30001-5_bb0335","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/S1567-5688(15)30001-5_bb0340","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1475-2840-13-26","article-title":"Residual macrovascular risk in 2013: what have we learned?","volume":"13","author":"Fruchart","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/S1567-5688(15)30001-5_bb0345","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1472-8206.2009.00764.x","article-title":"Combined therapy in the treatment of dyslipidemia","volume":"24","author":"Reiner","year":"2010","journal-title":"Fundam Clin Pharmacol"},{"issue":"14","key":"10.1016\/S1567-5688(15)30001-5_bb0350","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2165\/11208090-000000000-00000","article-title":"Fenofibrate: a review of its use in dyslipidaemia","volume":"71","author":"McKeage","year":"2011","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/S1567-5688(15)30001-5_bb0355","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.amjcard.2004.10.012","article-title":"Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)","volume":"95","author":"Grundy","year":"2005","journal-title":"Am J Cardiol"},{"issue":"9500","key":"10.1016\/S1567-5688(15)30001-5_bb0360","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/S1567-5688(15)30001-5_bb0365","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2217\/clp.13.69","article-title":"Fenofibrate and renal disease: clinical effects in diabetes","volume":"8","author":"Ting","year":"2013","journal-title":"Clin Lipidol"},{"issue":"3","key":"10.1016\/S1567-5688(15)30001-5_bb0370","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/S1567-5688(15)30001-5_bb0375","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"Chew","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/S1567-5688(15)30001-5_bb0380","article-title":"Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee","year":"2011"},{"issue":"7","key":"10.1016\/S1567-5688(15)30001-5_bb0385","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMc1006407","article-title":"Combination lipid therapy in type 2 diabetes","volume":"363","author":"Sacks","year":"2010","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/S1567-5688(15)30001-5_bb0390","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/eurheartj\/ehu107","article-title":"The ACC\/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC\/EAS guidelines for the management of dyslipidaemias 2011","volume":"35","author":"Ray","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/S1567-5688(15)30001-5_bb0395","series-title":"Assessment report for fenofibrate, bezafibrate, ciprofibrate, and gemfibrozil containing medical products","author":"European Medicines Agency (EMA)","year":"2011"},{"issue":"11","key":"10.1016\/S1567-5688(15)30001-5_bb0400","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1124\/dmd.30.11.1280","article-title":"Effects of fibrates on metabolism of statins in human hepatocytes","volume":"30","author":"Prueksaritanont","year":"2002","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/S1567-5688(15)30001-5_bb0405","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S1734-1140(10)70249-8","article-title":"Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances","volume":"62","author":"Krysiak","year":"2010","journal-title":"Pharmacol Rep"},{"issue":"4","key":"10.1016\/S1567-5688(15)30001-5_bb0410","doi-asserted-by":"crossref","first-page":"212","DOI":"10.5414\/CPP42212","article-title":"Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome","volume":"42","author":"Wysocki","year":"2004","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/S1567-5688(15)30001-5_bb0415","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.2337\/dc11-1811","article-title":"Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants","volume":"35","author":"Mychaleckyj","year":"2012","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/S1567-5688(15)30001-5_bb0420","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","article-title":"Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study","volume":"54","author":"Davis","year":"2011","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/S1567-5688(15)30001-5_bb0425","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s00125-012-2524-2","article-title":"Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience","volume":"55","author":"Bonds","year":"2012","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/S1567-5688(15)30001-5_bb0430","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2012.8439","article-title":"Lipid-modifying therapies and risk of pancreatitis: a meta-analysis","volume":"308","author":"Preiss","year":"2012","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/S1567-5688(15)30001-5_bb0435","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11883-012-0291-7","article-title":"How do we improve patient compliance and adherence to long-term statin therapy?","volume":"15","author":"Maningat","year":"2013","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/S1567-5688(15)30001-5_bb0440","first-page":"CD004371","article-title":"Interventions to improve adherence to lipid lowering medication","volume":"3","author":"Schedlbauer","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/S1567-5688(15)30001-5_bb0445","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.clinthera.2011.12.011","article-title":"Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis","volume":"34","author":"Degli Esposti","year":"2012","journal-title":"Clin Ther"},{"issue":"6","key":"10.1016\/S1567-5688(15)30001-5_bb0450","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1046\/j.1463-1326.2003.00297.x","article-title":"Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide\/metformin tablets as compared to glyburide co-administered with metformin","volume":"5","author":"Blonde","year":"2003","journal-title":"Diabetes Obes Metab"}],"container-title":["Atherosclerosis Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568815300015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568815300015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T12:41:46Z","timestamp":1668775306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567568815300015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":90,"alternative-id":["S1567568815300015"],"URL":"https:\/\/doi.org\/10.1016\/s1567-5688(15)30001-5","relation":{},"ISSN":["1567-5688"],"issn-type":[{"value":"1567-5688","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate\u2013statin combination therapy","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis Supplements","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1567-5688(15)30001-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}